Interpace Biosciences reports Q3 2026 revenue range
- Q3 2026 revenue expected between $10.1M and $10.4M
- QoQ growth of 11% to 14% compared to Q2 2026
- YoY growth of 15% to 18% compared to Q3 2025
IDXG
INTERPACE BIOSCIENCES, INC. SEC filings
Every EDGAR filing for INTERPACE BIOSCIENCES, INC. (IDXG), newest first, with AI summaries and stories.
- Ticker
- IDXG
- CIK
- 1054102
- Sector
- Medical devices
- Latest filing
- 3d
Next: 10-Q expected ~Nov 9 (deadline Nov 16)
Filings
FWPINTERPACE BIOSCIENCES, INC.IDXGDLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGDLIVE Interpace Biosciences reports Q3 2026 results.
- Q3 2026 results announced on Oct 14, 2026.
- Press release filed as Exhibit 99.1.
- Forward-looking statements included in the report.
S-1/AINTERPACE BIOSCIENCES, INC.IDXGDLIVE S-8INTERPACE BIOSCIENCES, INC.IDXGDLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 8-K/AINTERPACE BIOSCIENCES, INC.IDXGLIVE 4INTERPACE BIOSCIENCES, INC.IDXGLIVE 6 insider filings
Thomas W. Burnell, insider filing for IDXG
Show all 6
- 4Insider filing for IDXG
- 4Insider filing for IDXG
- 4Insider filing for IDXG
- 4Insider filing for IDXG
- 4Insider filing for IDXG
- 4Insider filing for IDXG
Thomas W. Burnell, reporting
8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 10-QINTERPACE BIOSCIENCES, INC.IDXGLIVE DEFA14AINTERPACE BIOSCIENCES, INC.IDXGLIVE DEF 14AINTERPACE BIOSCIENCES, INC.IDXGLIVE PRE 14AINTERPACE BIOSCIENCES, INC.IDXGLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 10-QINTERPACE BIOSCIENCES, INC.IDXGLIVE 10-K/AINTERPACE BIOSCIENCES, INC.IDXGLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 10-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 4INTERPACE BIOSCIENCES, INC.IDXGLIVE 1315 Capital II, L.P., insider filing for IDXG
1315 Capital II, L.P., reporting
4INTERPACE BIOSCIENCES, INC.IDXGLIVE Ampersand 2018 Limited Partnership, insider filing for IDXG
Ampersand 2018 Limited Partnership, reporting
8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 8-KINTERPACE BIOSCIENCES, INC.IDXGLIVE 10-QINTERPACE BIOSCIENCES, INC.IDXGLIVE